Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session - Thoracic cancers

Survival and treatment patterns in patients (pts) with locally advanced or metastatic NSCLC treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIS): Analysis of US insurance claims databases

Date

23 Nov 2019

Session

Mini Oral session - Thoracic cancers

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Ross Soo

Citation

Annals of Oncology (2019) 30 (suppl_9): ix183-ix202. 10.1093/annonc/mdz446

Authors

R.A. Soo1, T. Seto2, J.E. Gray3, P. Karimi4, A. Taylor5, W. Sawyer6, E. Thiel7, E. Marchlewicz7, M. Brouillette7

Author affiliations

  • 1 Department Haematology-oncology, National University Hospital, 119228 - Singapore/SG
  • 2 Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka/JP
  • 3 Department Of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, 33612 - Tampa/US
  • 4 Oncology Business Unit, AstraZeneca, 20878 - Gaithersburg/US
  • 5 Oncology Business Unit, AstraZeneca, Cambridge/GB
  • 6 Biometrics Oncology, AstraZeneca, Cambridge/GB
  • 7 Custom Data Analytics, IBM Watson Health, Cambridge/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.